- CME Logo


  1. Abshire TC, Brackmann H-H, Scharrer I et al. and the International Kogenate-FS Study Group. Sucrose formulated recombinant human anti-hemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy. Thromb Haemost. 2000;83:811-816.
  2. Addiego J, Kasper C, Abildgaard C et al. Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII. Lancet. 1993;342:462-464.
  3. Astermark J, Berntorp E, White GC, Kroner BL and the MIBS Study Group. The Malmö International Brother Study (MIBS): further support for genetic predisposition to inhibitor development. Haemophilia. 2001;7:267-272.
  4. Aygören-Pürsün E, Scharrer I, and the German Kogenate Study Group. A multicenter pharma-cosurveillance study for the evaluation of the efficacy and safety of recombinant factor VIII in the treatment of patients with hemophilia A. Thromb Haemost. 1997;78:1352-1356.
  5. Batorova A, Martinowitz U. Continuous infusion of coagulation factors. Haemophilia.2002; 8:170-177.
  6. Berntorp E. Second generation, B-domain deleted recombinant factor VIII. ThrombHaemost. 1997;78:256-260.
  7. Committee for Proprietary Medicinal Products (CPMP). Note for guidance on the clinical investigation of human plasma derived factor VIII and IX products. CPMP/BPWG/198/95, Rev. 1 (2000) Verfügbar unter: Stand: 21. Juli 2004.
  8. Eti E, Hayem G, De Bandt M et al. SLE in black patients from Africa and the French West Indies. Spectrum and race differences. Br JRheumatol. 1988;27:72-72.
  9. Fulcher CA, de Graaf Mahoney S, ZimmermanTS. FVIII inhibitor IgG subclass and FVIII poly-peptide specificity determined by immuno-blotting. Blood. 1987;69:1475-1480.
  10. Gill JC. The role of genetics in inhibitor formation. Thromb Haemost. 1999;82:500-504.
  11. Goodeve AC, Williams I, Bray GL, Peake IR for the RecombinateTM PUP Study Group. Relationship between factor VIII mutation type and inhibitor development in a cohort of previously untreated patients treated with recombinant factor VIII (RecombinateTM). Thromb Haemost. 2000;83:844-848.
  12. Groves FD, Linet MS, Travis LB, Devesa SS. Cancer Surveillance Series: non-Hodgkin’s lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst. 2000;92:1240-1251.
  13. Hay CR, Ludlam CA, Colvin BT et al. Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation. Thromb Haemost. 1998;79:762-766.
  14. Laub R, d iGiambattista M, Fondu P, Brackmann H-H, Lenk H, Scandella D. Restricted epitope specificity of FVIII inhibitors which appeared in previously treated hemophiliacs after infusion with OCTAVI DS Plus. Thromb Haemost.1997;91(suppl); 590. Abstract OC-2409.
  15. Lippert LE, Fisher LMA, Schook LB. Relationship of major histocompatibility complex class II genes to inhibitor antibody formation in hemophilia A. Thromb Haemost. 1990;64:564-568.
  16. Lorenzo JI, López A, Altisent C, Aznar JA. Incidence of factor VIII inhibitors in severe haemophilia: the importance of patient age. Brit J Haematol. 2001;113:600-603.
  17. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol. 1994;12:991-1045.
  18. Oldenburg J, Picard JK, Schwaab R et al. HLA genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors of factor VIII. Thromb Haemost 1997;77:238-242.
  19. Oldenburg J, Schröder J, Schmitt C. et al. Small deletion/insertion mutations within poly-A-runs of the factor VIII gene mitigate the severe haemophilia A phenotype. ThrombHaemost. 1998;79:452-453.
  20. Oldenburg J, Schwaab R. Molecular biology of coagulation factors. Semin ThrombHemost. 2001;27:313-324.
  21. Peerlinck K, Arnout J, Gilles JG et al. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate. Thromb Haemost. 1993;69:115-118.
  22. Rosendaal FR, Nieuwenhuis HK, van den Berg HM et al. A sudden increase in factor VIII inhibitor development in multi-transfused hemophilia A patients in the Netherlands. Blood. 1993;81:2180-2186.
  23. Scandella DH, Nakai H, Felch M et al. In hemophilia A and autoantibody inhibitor patients: the factor VIII A2 domain and light chain are most immunogenic. Thromb Res. 2001;101:377-385.
  24. Scandella D. New characteristics of anti-factor VIII inhibitor antibody epitopes and unusual immune responses to factor VIII. Sem ThrombHemost. 2002;28:291-295.
  25. Scharrer I, Bray GL, Neutzling O. Incidence of inhibitors in haemophilia A patients—a review of recent studies of recombinant and plasma-derived factor VIII concentrates. Haemophilia.1999;5:145-154.
  26. Scharrer I, Ehrlich HJ. Lack of evidence for in-creased inhibitor incidence in patients switched from plasma-derived to recombinant factor VIII. Haemophilia. 2001;7:346-348.
  27. Schwartz RS, Abildgaard CF, Aledort LM et al. Human recombinant DNA-derived antihemophil factor (factor VIII) in the treatment of hemophilia A. N Engl J Med. 1990;323:1800-1805.
  28. Sharathkumar A, Lillicrap D, Blanchette VS et al. Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A. J Thromb. Haemost. 2003;1:1228-1236.
  29. Tagariello G, Davoli PG, Gajo GB et al. Safety and efficacy of high-purity concentrates in haemophiliac patients undergoing surgery by continuous infusion. Haemophilia. 1999;5:426-430.
  30. van den Berg HM, Roosendaal G, Voorberg J, Mauser-Bunschoten EP. Inhibitor development in a multi-transfused patient with severe hemophilia A. Thromb Haemost. 1999;82:152.
  31. White II GC, Courter S, Bray GL et al. A multicenter study of recombinant factor VIII (RecombinateTM) in previously treated patients with hemophilia A. Thromb Haemost. 1997;77:660-667.
  32. White GC, DiMichele D, Mertens K et al., for the ISTH subcommittee. Utilization of PTPs, noninfected patients (NIPs) and PUPs in the evaluation of new FVIIII and FIX concentrates. Thromb Haemost. 1999;81:462.
  33. Yee TT, Lee CA. Is a change of factor VIII product a risk factor for the development of a factor VIII inhibitor? Thromb Haemost.1999;81:852.
  34. Astermark J, Oldenburg J et al. Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood 2006 [Epub ahead of print]
  35. Astermark J, Oldenburg J et al. Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood;107:3167-72.
  36. van der Bom JG, Mauser-Bunschoten EP et al. Age at first treatment and immune tolerance to factor VIII in severe hemophilia. Thromb Haemost 2003;89:475-9.
  37. Morado M, Villar A et al. Prophylactic treatment effects on inhibitor risk: experience in one centre. Haemophilia 2005;11:79-83.
  38. Santagostino E, Mancuso ME et al. Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study. Br J Haematol 2005;130:422-7.